Abstract: A cream moisturizer for resurfacing human skin is provided with a suspension of microcrystals of alumina (Al2O3) in a ratio of approximately 14 grams per ounce of moisturizer cream. The cream moisturizer is buffed into the epidermal layer of the skin with a closed-cell sponge pad driven by a vibrator. The alumina microcrystals buffs an epidermal layer off the skin to provide a soft smooth surface, thereby rejuvenating the skin.

Abstract: A process is claimed whereby an aqueous solution of agar, in which most (ideally all) 4-linked residues consist of 3,6-anhydro-L-galactose, is subjected to partial acid hydolysis and upon neutralization following the time appropriate for the chosen conditions, a low strength gel is obtained, from which, contrary to expectations, a polyagarobiose can be obtained by freeze-thawing and straining, thereby eliminating undesirable agaroid materials without the appropriate 3,6-anhydrogalactosyl content. The appropriate time of hydrolysis depends on initial gel strength, pH, counterion concentration and temperature. As an example, agar (gel strength 700 g/cm2, made to 1.86% solution) pH 3.25, counterion citrate (360 mg/L) at 96° C. requires 25 minutes to yield a material with an eventual gel stregth (1.5% solution) of 40 g/cm2. A stabilized product can be prepared by reducing terminal anhydrogalactosyl residues with sodium borohydride.

Abstract: Polymeric drug conjugates in controlled release matrices are provided which allow sustained concentrations of therapeutic agents within a treated area for a prolonged period. The polymeric drug conjugates hydrolytically degrade in the extracellular space in a controlled, pre-specified pattern, releasing active drug. The conjugates diffuse within the tissue reaching a greater distance from the matrix than free drug would, because of their reduced rate of clearance from the tissue via the capillary system.

Abstract: The present invention relates to skin care or personal wash cleanser compositions comprising mixtures of short and long-chain alpha-hydroxy acid esters in order to obtain long term benefit of shorter esters while masking short term drying effect of short chain esters.

Abstract: The present invention describes methods for preventing and treating sexual dysfunctions in patients by orally administering at least one &agr;-adrenergic receptor antagonist and at least one compound that elevates endogenous nitric oxide or endothelium-derived relaxing factor in vivo. The present invention also describes orally administrable compositions comprising at least one &agr;-adrenergic receptor antagonist and at least one compound that elevates endogenous nitric oxide or endothelium-derived relaxing factor in vivo. In the present invention, the &agr;-adrenergic receptor antagonist is preferably yohimbine or phentolamine, and the compound that elevates endogenous nitric oxide or endothelium-derived relaxing factor in vivo is preferably L-arginine.

Abstract: The present invention is concerned with a pharmaceutical formulation in a container, for example, a vial, prefilled cartridge, prefilled syringe or disposable pen, comprising approximately 0.01 to about 0.5% (w/v) amylin agonist, preferably pramlintide, in an aqueous system along with approximately 0.02 to about 0.5% (w/v) of an acetate, phosphate, citrate, or glutamate buffer to a pH of the final composition of approximately 3.0 to about 6.0 as well as approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol tonicifier; and, optionally, approximately 0.005 to 1.0% (w/v) of a preservative selected from the group consisting of m-cresol, benzyl alcohol, parabens and phenol. These formulations maintain stability upon storage under refrigerated or room temperature conditions. Such formulations can be further combined with insulin in the same syringe for administration to a patient.

Abstract: Biocompatible metallic medical devices having silanized surfaces coupled to nucleophile residues that release sustained, therapeutic amounts of nitric oxide to specific sites within a mammalian body are provided. Additionally, the biocompatible metallic medical devices can also be provided with anti-thrombogenic, lubricious coatings that release sustained, therapeutic amounts of nitric oxide. Moreover, the silanized metallic devices are surprisingly durable when exposed to harsh chemical methods often needed to bind nitric oxide-releasing functional groups to nucleophile residues. Furthermore, methods are provided for producing stable, silanized, sustained nitric oxide-releasing metallic medical devices.

Abstract: Topically applicable cosmetic/dermatological compositions suited for improvedly UV-photoprotecting human skin and/or hair against the deleterious effects of ultraviolet irradiation, advantageously oil-in-water emulsions, contain SPF-synergistically enhancing amounts of (a) at least one UV-screening benzotriazole-substituted silicon compound and (b) at least one UV-screening cinnamic acid derivative, formulated into (c) a topically applicable, cosmetically/dermatologically acceptable vehicle, diluent or carrier therefor.

Abstract: Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water-dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.

Abstract: Cosmetic composition for topical application to the skin comprising a hydroxyalkyl cyclodextrin, salicylic acid or salicylic acid derivative and water. The compositions herein provide improved anti-acne/anti-inflammatory activity together with reduced skin irritation.

Abstract: Compositions for oral use containing at least one zinc compound, at least one amino acid, a source of ascorbic acid which does not appreciably associate with zinc ions, and a base material. The compositions provide for slow release of zinc upon dissolution in the mouth. The amino acid provides the zinc compound(s) with a palatable taste and no aftertaste. The source of ascorbic acid provides Vitamin C without interacting with zinc and forming unpalatable by-products. A method for making such compositions is also described.

Abstract: A striped dentifrice stable to color bleeding, wherein at least one dentifrice component contains a colorant entrained in a matrix of synthetic wax particles having a melting point range as measured by DSC is between about 40° C. and about 135° C. and the peak endotherm temperature is at least about 65° C., whereby on storage no off-taste is detected in the dentifrice nor is there any observable colorant bleeding into any other dentifrice component.

Abstract: A composition containing an effective amount of nanoparticles selected from the group consisting of nanoscale sterols, nanoscale sterol esters, and mixtures thereof.

Abstract: An absorbent article includes a vapor permeable backsheet, a liquid permeable topsheet positioned in facing relation with the backsheet; and an absorbent body located between the backsheet and the topsheet. The absorbent body may include multiple zones of high air permeability. The absorbent article may also include a ventilation layer between the absorbent body and the backsheet and a surge management layer between the absorbent body and the topsheet. The article exhibits improved air exchange within the article during use. As a result, the article maintains the temperature and exhibits substantially reduced levels of hydration of the wearer's skin when in use which renders the skin less susceptible to the viability of microorganisms. The absorbent article may further include lotion formulations and/or treatment compositions thereon for maintaining or improving skin health.

Abstract: The present invention provides a pharmaceutical composition, kit, and method of forcing the reverse transport of cholesterol from peripheral tissues to the liver in vivo while controlling plasma LDL concentrations. The method includes the step of administering a therapeutically effective amount of a multiplicity of large liposomes comprised of phospholipids substantially free of sterol for a treatment period. The method optionally includes the step of periodically assaying plasma LDL concentrations with an assay during the treatment period to assess plasma atherogenic lipoprotein concentrations and obtain an atherogenic lipoprotein profile, and adjusting the administration in response to said profile. The large liposomes are dimensioned larger than fenestrations of an endothelial layer lining hepatic sinusoids in the liver so that the liposomes are too large to readily penetrate the fenestrations.

Abstract: A biological material is prepared for use in ophthalmology by steps of providing animal pericardium, subjecting the animal pericardium to multiple steps of freezing and thawing in a salt solution and incubating the animal pericardium in a solution of ammonia and ethyl alcohol. The multiple steps of freezing and thawing are conducted in a mixture of about 0.9% sodium chloride solution and distilled water in about 1:1 proportions of sodium chloride solution to distilled water. The incubating step is conducted in a mixture of 1% ammonia solution and 1% ethyl alcohol solution in about 1:1 proportions of ammonia solution to ethyl alcohol solution over a period of 48 to 72 hours.

Abstract: A cosmetic comprising: component (A): water-insoluble polymer particles having an average particle size of from 1 to 40 &mgr;m, comprising a shell part including a hydrophilic polymer and a core part including a hydrophobic polymer, and carrying an ultraviolet ray preventing agent on their surface or inside; and component (B): a cationic surface active agent.

Abstract: Improvedly photostable, topically applicable cosmetic/dermatological sunscreen compositions well suited for enhanced photoprotection of human skin and/or hair against the damaging effects of UV-A and UV-B irradiation, particularly solar radiation, comprise (i) a photoprotecting effective amount of at least one dibenzoylmethane UV-screening compound, and (ii) an amount of at least one silane or organosiloxane substituted by a benzylidenecamphor functional group effective to photostabilize said at least one dibenzoylmethane UV-screening compound (i).

Abstract: Disclosed is a method for transporting neurologic therapeutic agents to the brain by means of the olfactory neural pathway and a pharmaceutical composition useful in the treatment of brain disorders.

Abstract: The invention provides waterproof sunscreen compositions which include polymers of isoprene, butadiene and/or styrene, particularity conjugated dienes which may be subject to some degree of hydrogenation. A copolymer of two different conjugated dienes is preferred. The polymers may be selectively hydrogenated to produce polymers which have highly controlled amounts of unsaturation, thereby improving water resistancy.

Abstract: The invention relates to an incapacitant mixture comprising PAVA and a solvent, wherein the mixture capable of inducing temporary blindness in a human or animal. The mixture comprises less than 5 per cent PAVA and a solvent.

Abstract: A cosmetic system and technique are provided for improving the texture and appearance of an individual's skin. The system includes a light transport modifier that may be applied to a portion of the individual's epidermis. The light transport modifier is designed to displace naturally occurring water within that portion. Energy from an appropriate laser, infrared lamp, or the sun can then be directed to a treatment area beneath the epidermal layer without detrimental heat buildup in that area of the epidermis.

Abstract: The present invention relates to compositions primarily comprised of phospholipids, commercially known as lecithin, wherein the phospholipids form a solid mass—a liquid crystal phospholipid (LCP)—without the use of emulsifiers or other ingredients which are typically used as carriers for phospholipids. The invention also relates to the methods for making the phospholipid compositions. More particularly, the invention relates to a physical form of phospholipids and its use as a topical cosmetic skin bar, as a nutrient supplement or as a pharmaceutical dosage form if taken orally. Regardless of the exact shape of the new phospholipid composition, it comprises an amount of phospholipid equal to at least about 20% by weight of the total product. The new composition of the phospholipids appears as a solid which is produced by subjecting granular or powdered phospholipids to high levels of pressure which result in the formation of the solid phospholipid composition.

Abstract: The present invention relates to the use in cosmetics of rigid gels containing at least 20% by weight of one or more water-soluble or hydrophilic gelling agent(s) which may be obtained from the said water-soluble or hydrophilic gelling agent in the presence of water by mixing, blending, compression and extrusion in a twin-screw extruder.

Abstract: An electromagnetic wave absorber (4) of a material that causes a large dielectric or magnetic loss is disposed so as to surround a region between a high-frequency wave transmitting window (3) and an antenna (32) to suppress the formation of a sanding wave by suppressing the reflection of microwaves.

Abstract: These and other objects are attained by the subject invention wherein there is provided a carrier or product formed of a matrix having starch, sugar, fat, polyhydric alcohol and water in suitable ratios such that there exists a water activity of 0.6-0.75. The water activity of the product matrix is adjusted up or down so that the availability of water in the finished product is not detrimental to the included active ingredient, be it pharmaceutical, nutraceutical, or a vitamin mineral complex.

Abstract: A solid composition for topical application comprising, in an aqueous phase, a gelling system comprising (i) gellan gum, (ii) at least one other hydrocolloid chosen from the group formed by xanthan gum, carboxymethylcellulose, hydroxypropylcellulose, methylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, agar-agar, carrageenans, alginates, carob gum, guar gum, gum arabic, karaya gum, gum tragacanth, ghatti gum, pectins, gelatin, caseinates and hydroxypropylguar, and (iii) at least one amphiphilic polymer comprising at least one fatty chain and at least one hydrophilic unit.

Abstract: A cosmetic composition preferably an antiperspirant composition, in solid or soft-solid form has a continuous phase which contains a water-immiscible liquid carrier and also contains a structurant which is partially or fully esterified cellobiose of the formula 1

Abstract: An adhesive cosmetic strip is provided which includes a flexible water-insoluble substrate, an adhesive composition deposited onto the substrate and an agent interactive with water present in a sufficient quantity to induce a change of temperature of the strip. When applied to the skin, the strip is warmed by a reaction between water and an exothermic or endothermic agent held within the strip. Moisture within the skin or externally applied water penetrates the strip and will react with the agent to cause an increase or decrease in temperature.

Abstract: The present invention is directed to a high active sunscreen composition for topical application to human skin to protect the skin against UV radiation damage. The composition is particularly suitable for over-coating with make-up or other cosmetic compositions. More particularly, the present invention is directed to the use of a specific eutectic mixture of lower alkyl phthalamide that is surprisingly effective in solubilizing 4-(1,1-dimethylethyl)-4′-methoxydibenzoylmethane (PARSOL.RTM. 1789). Such concentrates solutions of PARSOL.RTM. 1789 can be used to formulate a more effective sunscreen, having a surprisingly increased sunscreen protection factor (SPF) and such that the PARSOL.RTM. 1789 is more effective over a longer period of time so that the sunscreen composition need not be applied to the skin as frequently.

Abstract: This invention relates to a two-part system useful for treating proteinaceous substrates. The two-part system has a first part comprising a water-soluble/dispersible reactive polyimido compound and a second part comprising a nucleophilic catalytic agent. The polyimido compounds may be selected from the group consisting of polysuccinimide compounds, polyglutimide compounds, and copolymers of thereof. The polyimido compound may also comprise a functionalizing moiety that provides functionality to the polyimido compound and is preferably derived from a nucleophilic moiety selected from the group consisting of amines, alcohols, phenols, thiols, and carboxylates; and a water-solubilizing/dispersing moiety that provides water-solubility and/or water-dispersibility to the polyimido compound and is preferably derived from a nucleophilic moiety selected from the group consisting of amines, alcohols, phenols, thiols, and carboxylates.

Abstract: 3-trimethylammonium-2-hydroxypropyl-N-chitosan (CHI-Q188) and related chitosan derivatives exhibit antimicrobial activity at concentrations as low as 10-20 &mgr;g/mL, an order of magnitude lower than the concentrations at which any previous chitosan derivative has been reported to exhibit antimicrobial activity. These compounds may be used as preservatives in cosmetic formulations, and as antimicrobial pharmaceutical agents.

Abstract: A stabilized sustained release oral solid dosage form which includes an effective amount of tramadol or a pharmaceutically acceptable salt thereof dispersed in a matrix of a hydrophobic material comprising a wax-like substance which was melted or softened during the preparation of the matrix, is cured at a temperature from about 35° C. to about 65° C. for a time period from about 4 to about 72 hours, such that the formulation, when subjected to in-vitro dissolution after exposure to accelerated storage conditions of at least one month at 40° C./75% RH, releases an amount of tramadol which does not vary at any given dissolution time point by more than about 20% of the total amount of tramadol released when compared to in-vitro dissolution conducted prior to subjecting the dosage form to the accelerated storage conditions.

Abstract: A drug delivery system for controlled release of a protein or polypeptide comprising a hydrophobic biodegradable polymer and a protein or polypeptide. A physical interaction is present between the polymer and the protein or polypeptide, thus, allowing protection and controlled release of the protein or polypeptide in-vivo. The drug delivery system may be prepared by a polymer precipitation technique or a microsphere technique.

Abstract: An injectable slow-release naltrexone formulation is provided comprising naltrexone in a poly(D,L-lactide) matrix with a small amount of residual ethyl acetate. Upon intramuscular injection of the composition, naltrexone is released in a controlled manner over an extended period of time. The composition finds use in the treatment of heroin addicts and alcoholics to reduce consumption of the abused substances.

Abstract: This invention comprises a one-phase cosmetic composition which can be made as a stick, gel or cream and which has low residue, low tack and improved fragrance substantivity. The cosmetic compositions are formed by (a) from 0.5-50 weight percent of a dimethicone copolyol ester compound soluble in propylene glycol; (b) from 50-98 weight percent of a gellant/solvent system which comprises a mixture of; (i) 0.5-4.0 weight percent dibenzylidene sorbitol; (ii) 0.05-1.0 weight percent of a co-gellant or structural integrity enhancer; (iii) 0.1-80 weight percent of a polyhydric alcohol solvent; (c) 0.5-10% of a small particle size zinc oxide having a particle size in the range of 20 nanometers-200 microns; and (d) 0.1-3.0% fragrance.

Abstract: Topically applying cosmetic/dermatological compositions well suited for both effective and SPF-enhanced UV-photoprotection of human skin and/or hair contain (a) an effective UV-photoprotecting amount of at least one UV-A and/or UV-B sunscreen and (b) an amount of immixture of ethylene polymers effective to enhance the SPF value of said at least one UV-A and/or UV-B sunscreen (a), said immixture of ethylene polymers (b) comprising (i) at least one carboxylated polyethylene and (ii) at least one polyethylene, formulated into a topically applicable, cosmetically/dermatologically acceptable vehicle, diluent or carrier therefor, advantageously formulated as an oil-in-water emulsion.

Abstract: Disclosed are a composition for inhibiting body odor which comprises trehalose and/or maltitol as an effective ingredient, a method for inhibiting body odor by using the composition, and an article incorporated with the composition.

Abstract: A plaster preparation comprising a synthetic rubber; a reinforcing agent based on silica or random styrene-butadiene, copolymer; a tackifier; salicylic acid or a pharmaceutically acceptable salt or ester thereof.

Abstract: A microemulsion containing (A) a highly polar and fat-soluble oil drug, a highly polar oil and a lowly polar oil, (B) a polyglycerol mono-fatty acid ester and (C) a water-soluble polyhydric alcohol, wherein the amount of (B) is 0.3 to 3 parts by weight based on one part by weight of (A) and the amount of (C) is 0.1 to 3 parts by weight based on one part by weight of the total amount of (A) and (B). The present invention makes it possible to make a microemulsion containing a highly polar and fat-soluble drug which is highly stable.

Abstract: A topical progesterone composition contains a concentration of progesterone and a concentration of emu oil. The emu oil acts as a transdermal vehicle to quickly and efficiently carry the progesterone into the body.

Abstract: This invention relates to water-soluble/dispersible reactive functionalized imido and polyimido compounds, wherein the polyimido compounds may be selected from the group consisting of polysuccinimide compounds, polyglutimide compounds, and copolymers of thereof. The polyimido compound comprises a functionalizing moiety F that provides functionality to the polyimido compound and is preferably derived from a nucleophilic moiety selected from the group consisting of amines, alcohols, phenols, thiols, and carboxylates; and a water-solubilizing/dispersing moiety that provides water-solubility and/or water-dispersibility to the polyimido compound and is preferably derived from a nucleophilic moiety selected from the group consisting of amines, alcohols, phenols, thiols, and carboxylates. The invention also pertains to a proteinaceous substrate to which the imido or polyimido compound has been covalently bonded and to a method for treating a proteinaceous substrate with the imido or polyimido compound.

Abstract: The present invention is directed to bioactive composition that induce the repair of damaged or diseased connective tissues upon contact of the damaged or diseased tissues with the composition in vivo. More particularly the present invention is directed to the use of a composition comprising an effective amount of endothelin to enhance the repair of damaged or diseased bone and cartilage tissues.

Abstract: A composition comprising a long-chain alkylpyrrolidone, a surfactant, and film-forming water-soluble polymer wherein the amounts of the components are such that on dilution with water, a clear liquid is formed. The composition may be used as a medium for agriculturally active ingredients as well as other active ingredients which are suitable for film formation, e.g., wood protectants, and the like.

Abstract: A warming and foaming anhydrous pulverulent composition, which is capable of being, hydrated, which comprises cosmetically acceptable powder and a binder, where the powder comprises solid particles of expanded polymers and the binder comprises an effective amount of an agent capable of giving off heat during hydration. The composition may be used, for example, for cleaning and/or caring for human skin.

Abstract: The application is directed to the treatment of one or more symptoms associated with drug withdrawal by administering desmethylselegiline.

Abstract: This invention is directed to a multi-vitamin and mineral supplement tailored to men and post-menopausal women, pre-menopausal women, and athletes which supplies the right amount of the right micronutrients at the right time to assure adequate intake of micronutrients needed for disease prevention and protection against nutritional losses and deficiencies due to lifestyle factors and common inadequate dietary patterns. The multi-vitamin and mineral supplement is comprised of vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, vitamin B1, vitamin B2, niacinamide, vitamin B6, vitamin B12, biotin, pantothenic acid, iron, iodine, magnesium, zinc, selenium, copper, chromium, potassium, choline, lycopene, and co-enzyme Q-10.

Abstract: This invention relates to water-soluble/dispersible reactive imido and polyimido compounds, wherein the polyimido compounds may be selected from the group consisting of polysuccinimide compounds, polyglutimide compounds, and copolymers of thereof. The polyimido compounds comprise a water-solubilizing/dispersing moiety that provides water-solubility and/or water-dispersibility to the polyimido compound and preferably is derived from a nucleophilic moiety selected from the group consisting of amines, alcohols, phenols, thiols, and carboxylates. The present invention also pertains to a proteinaceous substrate to which the imido or polyimido compound has been covalently bonded and to a method for treating a proteinaceous substrate with the imido or polyimido compound.

Abstract: The treatment is by means of nutritional supplements for the adrenal glands, liver and mast cells. The supplements may include potassium, magnesium, Vit B6, Vit B5, Vit C and EFA. A biological mechanism linking stress and allergies such as hayfever or other perennial or seasonal respiratory allergies is proposed and the effect of the treatment thereon is discussed.

Abstract: The present invention relates to external preparations containing a watercress extract which are excellent in the humectant effect and also capable of reducing skin irritation and giving a comfortableness of use even if a calefacient is blended. In particular, the present invention provides the external preparations containing a watercress extract with which one or more members selected from the group consisting of powdered capsicum, capsicum extract, capsicum tincture, capsaicin and nonanoic acid vanillylamide can be blended as calefacients.